摘要
目的探讨巴替非班对非ST段抬高急性冠状动脉综合征患者经皮冠状动脉介入术中及术后血小板聚集功能的影响。方法 53例择期行经皮冠状动脉介入术的非ST段抬高急性冠状动脉综合征患者,随机分为巴替非班组29例和安慰剂组24例,术中及术后24h分别给予巴替非班或安慰剂,比较2组用药前、用药后4h、用药后1d血小板聚集功能,观察术后30d内出血事件发生情况。结果 2组术前凝血指标比较差异无统计学意义(P>0.05);用药4h和1d后,巴替非班组血小板聚集率较安慰剂组明显降低(P<0.05),血小板聚集抑制率较安慰剂组明显升高(P<0.05);2组术后30d内出血事件发生率比较差异无统计学意义(P>0.05)。结论非ST段抬高急性冠状动脉综合征患者经皮冠状动脉介入术中及术后应用巴替非班疗效肯定,出血不良反应发生率低。
Objective To explore the effect of batifiban on platelet aggregation during and after percutaneous coronary intervention （PCI） in patients with non-ST segment elevation acute coronary syndrome （ACS）. Methods Fifty-three patients with non-ST segment elevation ACS receiving PCI were administrated with batifiban （batifiban group, n： 29） and placebo （placebo group, n=24） during and 24-hour after operation. The related platelet aggregation parameters were detected before administration, and 4 hours and 1 day after administration in two groups. The hemorrhage was observed in 30 days after operation. Results There was no significant difference in coagulation function indexes between two groups before operation （P 〉0.05）. The platelet aggregation rate was significantly lower and platelet aggregation inhibition rate was significantly higher in batifiban group than that in placebo group 4 hours and 1 day after operation （P〈0.05）. There was no significant difference in hemorrhage between two groups （P〉0.05）. Conclusion Batifiban is effective in PCI for non-ST segment elevation ACS with lower incidence of hemorrhage.
出处
《中华实用诊断与治疗杂志》
2013年第1期11-13,共3页
Journal of Chinese Practical Diagnosis and Therapy
基金
国家自然科学基金(81000130)
国家自然科学基金(81000091)
北京市卫生局青年科学研究资助项目(QN2010-010)
